These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17703223)

  • 1. Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease.
    Park JW; Leithäuser B; Mrowietz C; Jung F
    Int J Impot Res; 2008; 20(2):150-6. PubMed ID: 17703223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.
    Rosano GM; Aversa A; Vitale C; Fabbri A; Fini M; Spera G
    Eur Urol; 2005 Feb; 47(2):214-20; discussion 220-2. PubMed ID: 15661417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease.
    Bellotto F; Ruscazio M; Bonanni G; Montisci R; Cutolo A; Sarais C; Setzu T; Borrini A; Iliceto S
    Int J Impot Res; 2008; 20(2):168-72. PubMed ID: 17703220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
    Gazzaruso C; Solerte SB; Pujia A; Coppola A; Vezzoli M; Salvucci F; Valenti C; Giustina A; Garzaniti A
    J Am Coll Cardiol; 2008 May; 51(21):2040-4. PubMed ID: 18498958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury.
    Giuliano F; Sanchez-Ramos A; Löchner-Ernst D; Del Popolo G; Cruz N; Leriche A; Lombardi G; Reichert S; Dahl P; Elion-Mboussa A; Casariego J
    Arch Neurol; 2007 Nov; 64(11):1584-92. PubMed ID: 17846260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.
    Shabsigh R; Kim ED; Rosen RC; Shinghal R; Natanegara F; Muram D; Wong DG
    Int J Impot Res; 2008; 20(6):554-60. PubMed ID: 18997808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.
    Hatzichristou D; Gambla M; Rubio-Aurioles E; Buvat J; Brock GB; Spera G; Rose L; Lording D; Liang S
    Diabet Med; 2008 Feb; 25(2):138-46. PubMed ID: 18290855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction.
    Foresta C; Ferlin A; De Toni L; Lana A; Vinanzi C; Galan A; Caretta N
    Int J Impot Res; 2006; 18(5):484-8. PubMed ID: 16541115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil for treatment of erectile dysfunction in men on antidepressants.
    Segraves RT; Lee J; Stevenson R; Walker DJ; Wang WC; Dickson RA
    J Clin Psychopharmacol; 2007 Feb; 27(1):62-6. PubMed ID: 17224715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile dysfunction in healthy subjects predicts reduced coronary flow velocity reserve.
    Borgquist R; Gudmundsson P; Winter R; Nilsson P; Willenheimer R
    Int J Cardiol; 2006 Sep; 112(2):166-70. PubMed ID: 16271777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study.
    Aversa A; Greco E; Bruzziches R; Pili M; Rosano G; Spera G
    Int J Impot Res; 2007; 19(2):200-7. PubMed ID: 16943794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Observation of safety and efficacy of tadalafil for men with erectile dysfunction].
    Zhu XW; Li FY; Fang JJ
    Zhonghua Nan Ke Xue; 2006 May; 12(5):421-3, 427. PubMed ID: 16755872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients.
    Gazzaruso C; Pujia A; Solerte SB; Amici ED; Emanuele E; Falcone C; Geroldi D; Giustina A; Garzaniti A
    Int J Impot Res; 2006; 18(3):311-5. PubMed ID: 16224493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study.
    De Bon E; Bonanni G; Saggiorato G; Bassi P; Cella G
    Angiology; 2010 Aug; 61(6):602-6. PubMed ID: 20395237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
    Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
    Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
    DeBusk RF
    Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.
    La Vignera S; Calogero AE; Cannizzaro MA; Condorelli R; Noto Z; Vicari E
    Minerva Endocrinol; 2006 Dec; 31(4):251-61. PubMed ID: 17213792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.